A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature

@article{Mura2021AB,
  title={A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature},
  author={Cameron Mura and Saskia Preissner and Robert Preissner and Philip E. Bourne},
  journal={Frontiers in Pharmacology},
  year={2021},
  volume={12}
}
This Perspective examines a recent surge of information regarding the potential benefits of acid-suppression drugs in the context of COVID-19, with a particular eye on the great variability (and, thus, confusion) that has arisen across the reported findings, at least as regards the popular antacid famotidine. The degree of inconsistency and discordance reflects contradictory conclusions from independent, clinical-based studies that took roughly similar approaches, in terms of both experimental… 

Figures from this paper

Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients

A large, international, multi-center retrospective study reported here, sampling over 250,000 COVID-19 cases, hopefully helps clarify the possible value of clinically-approved histamine antagonists such as famotidine.

Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients

A large, multi-center retrospective study reported here, sampling over 250,000 COVID-19 cases internationally, hopefully helps clarify the possible value of clinically-approved histamine antagonists such as famotidine.

Experimental Search for New Means of Pathogenetic Therapy COVID-19: Inhibitor of H2-Receptors Famotidine Increases the Effect of Oseltamivir on Survival and Immune Status of Mice Infected by A/PR/8/34 (H1N1)

The use of famotidine in combination with oseltamivir can increase survival, improve the dynamics of animal weight, reduce thelevel of NKT cells and increase the level of naive T-helpers.

Inhibitors of SARS-CoV-2 PLpro

The conserved structure and function of PLpro and the ongoing efforts to design small molecule PLpro inhibitors that exploit this knowledge are discussed, suggesting that PLpro is an excellent drug target for next generation antivirals.

References

SHOWING 1-10 OF 55 REFERENCES

More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?

  • R. Malone
  • Medicine, Biology
    Digestive Diseases and Sciences
  • 2021
It is clearly established that famotidine administration at the standard GERD treatment doses does not provide a significant benefit in reducing the risk of serious illness, death, and intubation for hospitalized COVID-19 patients.

Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study

This territory-wide study investigated whether PPI or famotidine use was associated with a higher risk of severe disease using propensity score matching and found conflicting findings.

Repurposed GI Drugs in the Treatment of COVID-19

There is still little knowledge on the potential of famotidine and omeprazole as repurposed drugs to treat COVID-19 and the evidence of these common GI drugs and their potentials is highlighted.

Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis

It is found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients.

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

No evidence of a reduced risk of COVID-19 outcomes among hospitalized CO VID-19 patients who used famotidine compared to those who did not or compared to PPI or hydroxychloroquine users is found.

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.

It is found that there is no evidence of a reduced risk of COVID-19 outcomes among hospitalized CO VID-19 patients who used famotidine compared with those who did not or compared with PPI or hydroxychloroquine users.

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

This phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation, and main outcomes patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase and complete blood count were measured.

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

It is proposed that the principal mechanism of action of famotidine for relieving COVID-19 symptoms involves on-target histamine receptor H2 activity, and that development of clinical CO VID-19 involves dysfunctional mast cell activation and histamine release.
...